Q2 – Alligator Bioscience

2025-07-10

Regulatory

Alligator Bioscience AB reports financial results for Q2 2025 and provides a business update

GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 ...

2024-07-112024-07-11

Regulatory

Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...

2023-07-13

Regulatory

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2022-07-12

Regulatory

· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...

2021-07-13

Regulatory

Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...

2020-07-13

Regulatory

Promising safety data for ATOR-1015 "With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinica ...

2019-07-11

Regulatory

Competitive safety data for ADC-1013. Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 in ...

2018-07-12

Regulatory

Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...

2017-08-23

Regulatory

“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...